Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue

NCT05767255 on ClinicalTrials.gov · last registry update 2023-03-14

A small phase 3 — 66 participants, against a typical 424. Its estimated completion date, 30 August 2023, has passed with no update to the record. Primary outcome, as filed: To compare the percentage of hypoglycemia. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hospital Universitario San Ignacio
Sponsor type: Other
Enrollment: 66
Started: 2022-12-01
Primary completion: 2023-08-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To compare the percentage of hypoglycemia

Conditions studied

Diabetes Mellitus, Type 2 Treated With Insulin

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.